Together with the discovery of high TIGIT expression in the TIL and peripheral blood of patients with NSCLC, these data support moving an immunotherapy agent targeting TIGIT into phase I clinical trials. The gene discussed is TIGIT; the disease is non-small cell lung carcinoma.